Conference Coverage

Empiric warfarin adjustment cut drug-drug interactions with antimicrobials


 

AT ASM MICROBE 2016

References

Dr. Ha and his coauthors noted that the uncontrolled nature of the pre-post study design was one limitation of the study. Also, the real-world design of the study meant that investigators could not control for diet, comorbidities, and other factors that have the potential to affect INR. “Implementing a process to identify high-risk antimicrobial-warfarin DDIs and provide guidelines for empiric warfarin dose adjustment … can improve INR time within therapeutic range,” noted Dr. Ha and his coauthors.

The study authors reported no external sources of funding and no conflicts of interest.

koakes@frontlinemedcom.com

On Twitter @karioakes

Pages

Recommended Reading

VIDEO: HOPE-3 trial expands scope of primary cardiovascular prevention
MDedge ObGyn
Cardiovascular consequences of extreme prematurity persist into late adolescence
MDedge ObGyn
Exercise linked to fewer cardiovascular events in nonmetastatic breast cancer patients
MDedge ObGyn
Statins improve ovarian cancer survival
MDedge ObGyn
Menopause and cardiovascular risk examined in type 1 diabetes
MDedge ObGyn
Testosterone might counteract chemotherapy heart damage
MDedge ObGyn
Psoriasis cardiovascular risk parallels type 2 diabetes
MDedge ObGyn
VIDEO: Moderate LDL, SBP reductions slash cardiovascular events 90% over time
MDedge ObGyn
A quarter of hypertensive Medicare enrollees are nonadherent
MDedge ObGyn
Decision rule identifies unprovoked VTE patients who can halt anticoagulation
MDedge ObGyn